Venrock

Venrock Research Overview Venrock is one of Silicon Valley's most storied venture capital institutions, tracing its origins to the Rockefeller family's formalization of technology investing in 1969. Named for a contraction of "Venture" and "Rockefeller," the firm was founded by Laurance S. Rockefeller, who began backing early-stage businesses as early as 1934, growing an $8.7M portfolio to over $28M by the late 1950s. Today, Venrock manages approximately $3 billion in assets under management across its main fund and the affiliated Venrock Healthcare Capital Partners (VHCP), a crossover fund focused on public and late-stage private biotechnology and life sciences companies. Over its 55+ year history, Venrock has invested in more than 440 companies, generating 125 IPOs and 186 acquisitions. The firm was an early investor in Apple, Intel, Gilead Sciences, and Illumina — investments that define the gold standard of early-stage venture. Today the firm maintains that same orientation: finding category-defining companies at the earliest stages across technology and healthcare. Investment Thesis Venrock backs bold founders in technology and healthcare who are building companies that will define the future of their industries. The firm operates two core practice areas: Enterprise, AI & Frontier Systems: Partners Ethan Batraski and Nick Beim focus on early-stage companies building AI infrastructure, frontier technology, defense/aerospace, cybersecurity, fintech, and developer tools. Batraski, formerly VP of Product and Design at Box (through IPO) and a senior leader at Facebook overseeing a $15B+ run-rate business, focuses on AI and frontier systems — investments include Astranis (satellite broadband), Astronomer (Apache Airflow data orchestration), Atom Computing (quantum computing), Archetype AI (physical AI), Euclid Power (grid intelligence), and Skyryse (aviation automation). Beim focuses on AI, software, fintech, and defense. Healthcare & Life Sciences: Led by Bryan Roberts (partner since 1997), Bob Kocher, Bong Koh, and Nimish Shah. Roberts is one of the most respected healthcare VCs in the country, with investments spanning therapeutics, genomics, and health system modernization — current board roles include Aledade, Devoted Health, Lyra Health, Included Health, SmithRx, Suki.ai, and Kelonia Therapeutics. Bob Kocher focuses on health tech and services. Bong Koh (MD, MBA) and Nimish Shah lead Venrock Healthcare Capital Partners, an affiliated crossover fund targeting small-cap public biotechnology and late-stage private life sciences companies — VHCP raised $500M for a new vehicle (VHCP XP) in November 2024. Stage Focus Venrock primarily invests at the Seed and Series A stages for its main fund, with check sizes ranging from $500K to $20M. The firm occasionally participates in pre-seed rounds for exceptional founders and maintains meaningful follow-on reserves through Series B+. VHCP operates at crossover and late-stage with substantially larger check sizes (average post-IPO round size $112M per Tracxn data). Check Size Main fund: $500K–$20M (targeting 15-20% ownership at entry) VHCP: Much larger crossover/late-stage investments Lead Tendency Venrock leads and co-leads rounds. The firm typically takes board seats and plays a deeply active role in portfolio companies' strategic development. Recent evidence: co-led GenLogs' $60M Series B (February 2026) alongside HOF Capital. Recent Activity Venrock is actively deploying. The firm made 20 investments in 2025 and 5 already by March 2026. Recent highlights: GenLogs (Series B, February 2026): Supply chain intelligence platform using truck sensor data; Venrock co-led $60M round alongside Battery Ventures, IVP, HOF Capital Angitia (Series D, February 2026): Via VHCP Maze Therapeutics (Private Placement, September 2025): Biotech; participated in oversubscribed $150M round via VHCP Astronomer (Series D, May 2025): Apache Airflow data orchestration platform; $93M round Zero Networks (Series C, June 2025): Network microsegmentation; $55M round (originally invested at Series A, 2022) Taysha Gene Therapies : Follow-on investment 2025 The most recent exit was TAE Technologies (December 18, 2025). The most recent acquisition was Avadel Pharmaceuticals (acquired by Alkermes for $2.1B, October 2025) and Border0 (acquired by Tailscale, March 2026). Portfolio Highlights Current Active Portfolio (standouts): Altruist — wealth management platform for financial advisors (unicorn) Salsify — product content management for commerce (unicorn) Cloudflare — network security and performance (NASDAQ: NET, IPO 2019) Devoted Health — Medicare Advantage insurer Aledade — primary care physician network Lyra Health — employer mental health benefits platform Included Health (formerly Grand Rounds) — healthcare navigation Dataminr — real-time event detection from public data Astronomer — Apache Airflow data orchestration Zero Networks — network microsegmentation Historic Exits (selected): Apple — early investor; iconic exit Intel — early investor; foundational semiconductor company Dollar Shave Club — acquired by Unilever for $1 billion Receptos — acquired by Celgene for $7.2 billion Gilead Sciences — IPO; leading biopharmaceutical Illumina — IPO; genomic sequencing leader athenahealth — IPO; health IT acquired by Veritas/Elliot Juno Therapeutics — CAR-T pioneer; acquired by Bristol-Myers Squibb AppNexus — ad tech; acquired by AT&T/Xandr Nest — smart home; acquired by Google Check Point Software — cybersecurity; NASDAQ IPO DoubleClick — ad tech; acquired by Google 23andMe — consumer genomics; IPO via SPAC Venrock has 16 current unicorns in its portfolio. Team Bryan Roberts – Partner (since 1997): One of the most prolific healthcare VCs in the US. Focuses on therapeutics, genomics, digital health, and health system modernization. Board: Aledade, Devoted Health, Lyra Health, Included Health, SmithRx, Suki.ai, Kelonia Therapeutics, Encoded Therapeutics, Element Biosciences. Ethan Batraski – Partner: AI and frontier systems. Former VP Product & Design at Box (through IPO), senior leadership at Facebook ($15B+ run-rate). Board/investments: Astranis, Astronomer, Atom Computing, Euclid Power, Skyryse, Archetype AI, Oumi. Nick Beim – Partner: AI, software, fintech, and defense investments. Bob Kocher – Partner: Health tech and services. Former Special Assistant to the President for Healthcare Policy (Obama White House), former McKinsey partner. Bong Koh, MD, MBA – Partner (Venrock Healthcare Capital Partners, since 2009): Public and crossover biotech. Leads VHCP investments. Nimish Shah – Partner (Venrock Healthcare Capital Partners, since 2013): Small-cap public biotechnology. Leads VHCP investments alongside Koh. Todd Graham – Vice President Decision Process Venrock is a consensus-based partnership where deals require buy-in across the relevant partners. The firm emphasizes deep due diligence and long-term relationships with founders. Partners take board seats and remain actively involved across the company lifecycle. Decision timelines are typically 1-2 months for new investments. Geographic Focus Primarily United States, headquartered in Palo Alto, CA with additional offices in New York City. The firm invests across the US with concentration in the SF Bay Area and New York metro area. Selective international investments in life sciences.